Prevalence and Maintenance of Clinical Remission in Patients with Severe Uncontrolled Asthma Undergoing Biologic Therapies. (PubMed, Open Respir Arch) - Oct 6, 2026 - "We retrospectively evaluated 50 patients who initiated first-line biologic therapy with omalizumab, mepolizumab, or reslizumab between 2015 and 2019. Although remission was achieved in approximately one-quarter of patients, it was maintained in fewer than half. Our baseline FVC and ACT findings require confirmation in larger studies."
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
Beatriz Recio-Moreno; Elena Dorado-Fonseca; Javier de Miguel-Díez; Julia García de Pedro; Laura de Miguel-Rodríguez; María Jesús Buendía-García; Zichen Ji
|